Retatrutide clinical trials near me: how to actually find one

Last updated 2026-07-25

How do I find a retatrutide clinical trial near me?

Go straight to ClinicalTrials.gov and search the retatrutide development code, LY3437943, or the name itself. The main phase 2 obesity trial is registered as NCT04881760, and it lists dose arms, comparator groups, and the injection route used in the study ^{[1] [2]}. Two later-phase trials, NCT05929066 and NCT05882045, are also publicly registered with their own enrollment criteria, comparator arms, and endpoints ^{[3] [4]}. Each listing has a "Study Locations" section near the bottom of the page. That's where you'll see actual site names, cities, and recruiting status. Some trials list dozens of sites across the US and internationally, others are limited to a handful of academic medical centers. Status changes constantly: a site marked "recruiting" today might be closed to new participants in a month, so check back rather than trusting a stale printout or a forum post. If you don't see an open site near you, that's not unusual. Phase 3 obesity and diabetes trials tend to cluster around large endocrinology and metabolic research centers, not every city has one. Don't assume that means retatrutide is unavailable everywhere. It means the sponsor hasn't opened a site in your area for that particular protocol. Don't substitute a Google search for "retatrutide clinical trials near me" for the primary registry. Gray-market vendor sites sometimes use trial language and cite the real NEJM data to make their products sound legitimate, and Retatrutide Report's guide to retatrutide's legal status walks through why that marketing doesn't change the legal status of what they're selling.

Is retatrutide FDA approved for weight loss or diabetes?

No. A query of Drugs@FDA, the FDA's own database of approved drug products, for the generic name retatrutide returns no approved product for any indication ^[5]. That's true for obesity, type 2 diabetes, or anything else. Every dose, every result you've read about, comes from clinical trials, not from an approved drug you can be prescribed at a pharmacy. This matters because approval status is exactly what separates a drug you can get from a doctor from a compound you can only access inside a study. Semaglutide is approved and sold as Ozempic and Wegovy. Tirzepatide is approved as Mounjaro and Zepbound. Orforglipron, a newer oral GLP-1 drug, was approved as Foundayo under NDA 220934 in six strengths from 0.8 mg to 17.2 mg ^[6]. Retatrutide has none of that. It sits entirely in the investigational category, meaning its only lawful path into a human body in the US right now is a registered trial protocol.

Can a compounding pharmacy legally make retatrutide?

No, and this isn't a gray area. Section 503A of the Food, Drug and Cosmetic Act lets a compounding pharmacy make a drug from a bulk substance only through a specific cascade: the substance has to comply with an applicable USP or NF monograph if one exists, or if no monograph exists it has to be a component of an FDA-approved drug, and only if neither of those applies can it come from the 503A Bulks List ^[7]. Retatrutide fails all three tests. There's no USP monograph for it, it isn't a component of any approved drug because no approved retatrutide drug exists, and it's not on the Bulks List. The final 503A Bulks List, published at 21 CFR 216.23, contains exactly six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide ^[8]. Not one of them is a peptide. Retatrutide isn't there and never has been. Separately, even if an ingredient did qualify under the cascade, 503A also requires that the bulk drug substance come from a facility registered under section 510 of the FD&C Act and arrive with a valid certificate of analysis ^[7]. Research-use-only material from an unregistered overseas supplier fails this requirement regardless of anything else about the ingredient. That's the actual reason a compounding pharmacy can't lawfully touch it, more than a technicality about paperwork. The 503B list, which governs larger outsourcing facilities rather than standard compounding pharmacies, is a separate roster under 21 CFR 216.24, and retatrutide isn't on that one either ^[9]. FDA maintains a public list of bulk substances nominated for 503A compounding, broken into interim categories, and you can check it yourself: retatrutide does not appear ^{[10] [11]}.

Why was retatrutide considered for the compounding bulks list, or was it?

It wasn't, and this is a common point of confusion. FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 to consider seven peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax, and epitalon ^[12]. Retatrutide was not among them and has never been nominated for that list. Even for the peptides that were reviewed, a favorable committee vote doesn't create a legal compounding pathway by itself. Advisory committee recommendations are non-binding, and actually adding a substance to the Bulks List requires full notice-and-comment rulemaking, a process that can take years ^[12]. So even in the best case for those seven peptides, nothing changes overnight. For retatrutide, which was never even on the agenda, there's no pending process to point to at all.

What did the retatrutide trials actually show?

The headline number comes from the phase 2 obesity trial published in the New England Journal of Medicine: at 48 weeks, the 12 mg dose produced a mean weight reduction of 24.2 percent, compared with 2.1 percent for placebo, using weekly subcutaneous injection ^[1]. That's a substantial difference, and it's the reason retatrutide gets so much attention. Mechanistically, retatrutide is a triple agonist, acting at the GIP, GLP-1, and glucagon receptors ^[1]. That's different from semaglutide, which acts only on the GLP-1 receptor, and from tirzepatide, which combines GIP and GLP-1 but skips glucagon. The added glucagon receptor activity is the theoretical reason for retatrutide's larger effect size in early trials, since glucagon receptor agonism is linked to increased energy expenditure in addition to appetite suppression. | Drug | Receptor targets | Approval status |

What dose did the retatrutide trials use, and can a doctor prescribe that?

The phase 2 obesity trial tested weekly subcutaneous injections at multiple doses, with the 12 mg arm producing the largest effect at 24.2 percent weight reduction at 48 weeks ^[1]. That's a trial-administered dose, given under a specific protocol, with study staff controlling reconstitution, storage, and injection technique, and with lab monitoring built into the schedule. No doctor in the United States can lawfully prescribe that dose, or any dose, of retatrutide outside a registered trial. There's no approved product to write a prescription for, and as covered above, no compounding pathway exists either. If you've seen dosing charts or protocols online that describe retatrutide dosing schedules, treat them as historical trial data, not medical advice you can act on. Retatrutide Report's dosage chart and dosage calculator pages document what trials used for reference purposes, and the same caveat applies there: it's what was studied, not something a clinician can lawfully give you right now.

Why can't I just get retatrutide online if trials aren't near me?

Because a research-use-only label on a vendor's website doesn't change what the product legally is. Under 21 U.S.C. 355, a new drug can't be introduced into interstate commerce without an approved application, and retatrutide has none ^[13]. Selling it for human use, regardless of the label on the vial, runs into that wall directly. FDA has been explicit that a disclaimer doesn't defeat drug status if the seller's marketing says otherwise. In a March 2026 warning letter to a peptide seller, FDA wrote that despite research-use-only and not-for-human-consumption labeling, evidence from the company's website established that its products were intended to be drugs for human use, and the letter specifically named retatrutide sold on that site ^[14]. Under 21 CFR 201.128, intended use is established by labeling claims, advertising, and oral or written statements made by the seller, not by a disclaimer buried in the fine print ^[15]. If a site talks about fat loss, appetite suppression, or metabolic benefits, that language is what determines regulatory status, not the disclaimer sitting next to it. FDA also publishes a policy on personal importation of unapproved drugs, which is the specific rule that applies if you're considering ordering research peptides from an overseas supplier ^[16]. It doesn't create a loophole. It describes limited discretion FDA sometimes exercises for personal medical products in narrow circumstances, and an unapproved investigational obesity peptide with no monograph and no approved reference product doesn't fit that description. For the full breakdown of why gray-market retatrutide sales aren't a legal option no matter how the listing is worded, see Retatrutide Report's dedicated legal-status article.

What are my legal options if there's no trial near me?

You have three real paths, and none of them is ordering research peptides online. First, keep checking ClinicalTrials.gov periodically. New sites open for existing protocols, and new retatrutide studies get registered as the drug moves through later trial phases. A search today that turns up nothing nearby might turn up a site six months from now. Second, talk to a doctor about approved incretin drugs that already have full safety and efficacy data behind them. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are both FDA approved with published trial data, and orforglipron (Foundayo) is now an approved oral option for patients who'd rather avoid injections ^[6]. None of these hits the 24.2 percent mark retatrutide showed at its top dose, but they're legal, monitored, and something a clinician can actually prescribe and adjust based on how you respond. Third, look at NIDDK's federal guidance on evidence-based weight management for a neutral, non-commercial starting point on options that don't depend on an investigational drug being available . It's not exciting reading compared to trial headlines, but it's honest, and it doesn't require you to gamble on an unregulated product with no certificate of analysis and no oversight. What I'd actually do in this situation: check the trial registries first, because a supervised trial with real monitoring beats anything else on this list if you can get into one. If nothing's open near you, have the approved-drug conversation with a doctor rather than waiting around or looking overseas. Waiting for retatrutide specifically, when tirzepatide and semaglutide already have years of real-world safety data behind them, often isn't the trade-off it looks like from a headline.

What are the risks of using unregulated retatrutide from a vendor?

You lose every safeguard that makes a drug worth taking. No certificate of analysis means you don't know the actual concentration, purity, or sterility of what's in the vial. Research-use-only material from an unregistered supplier fails FDA's own bulk substance requirements regardless of anything else, precisely because there's no verification step behind it ^[7]. You also lose clinical monitoring. In the actual phase 2 trial, participants had scheduled visits, lab work, and staff trained to catch adverse effects early ^[1]. A vendor selling a vial with a research-use-only sticker offers none of that. If something goes wrong, from an injection site infection to an unexpected reaction, you're on your own, with a product whose actual contents were never independently verified. Retatrutide Report's side effects page covers what's actually been documented in trial populations, which is the only population with real safety data behind it.

How does retatrutide's trial status compare to tirzepatide and semaglutide's early days?

Every approved GLP-1 drug went through this exact stage once. Semaglutide and tirzepatide were both investigational compounds, registered in ClinicalTrials.gov, tested in exactly the same phase 2 and phase 3 structure retatrutide is going through now, before FDA approval turned them into prescribable drugs ^[6]. The difference is time and completed regulatory review, not some special exception. Retatrutide is currently in later-phase registered trials, with NCT05929066 and NCT05882045 giving two independent, publicly available records of dosing, comparator arms, and endpoints being tested ^{[3] [4]}. That's a normal, expected stage in drug development. It's also exactly why patience, not gray-market purchasing, is the rational response if you're following this drug closely.

Frequently asked questions

Is there a retatrutide clinical trial I can join right now?

Possibly, depending on where you live and current recruiting status. Search ClinicalTrials.gov for NCT04881760, NCT05929066, or NCT05882045 and check the "Study Locations" section on each listing for open sites near you. Status changes often, so a site closed today might reopen for a new cohort later.

Does retatrutide have FDA approval yet?

No. A Drugs@FDA search for retatrutide returns no approved product for any use, including obesity or type 2 diabetes. Every result you've seen reported comes from clinical trials, not from an approved, prescribable drug.

Can I get retatrutide from a compounding pharmacy?

No. Retatrutide has no USP monograph, isn't a component of any approved drug, and isn't on the 503A Bulks List, which contains only six substances, none of them peptides. All three 503A pathways are closed, so no US compounding pharmacy can legally make it.

Why do some websites sell retatrutide labeled research use only?

That label doesn't make the sale legal if the site's marketing implies human use. FDA has stated in a 2026 warning letter that promotional claims, not disclaimers, establish intended use, and specifically named retatrutide sold under a research-use-only label in that enforcement action.

What weight loss results did retatrutide show in trials?

In the phase 2 obesity trial published in the New England Journal of Medicine, the 12 mg dose produced a mean 24.2 percent weight reduction at 48 weeks, versus 2.1 percent for placebo, using weekly subcutaneous injection.

Is retatrutide the same as tirzepatide or semaglutide?

No. Retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptors. Tirzepatide acts on GLP-1 and GIP only. Semaglutide acts on GLP-1 only. The added glucagon receptor activity is the proposed reason for retatrutide's larger effect size in early trials.

Was retatrutide considered for the FDA compounding bulks list?

No. FDA's Pharmacy Compounding Advisory Committee reviewed seven other peptides in July 2026 (BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, epitalon) for the 503A Bulks List. Retatrutide wasn't on that agenda and has never been nominated for the list.

Can a doctor prescribe retatrutide off-label?

No. Off-label prescribing applies to approved drugs used outside their labeled indication. Retatrutide has no FDA approval at all, so there's no approved product for a doctor to prescribe off-label in the first place, inside or outside a trial.

What's a legal alternative to retatrutide while I wait for approval or a trial slot?

FDA-approved incretin drugs: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and the newer oral option orforglipron (Foundayo, NDA 220934). None matches retatrutide's trial results exactly, but all have published safety data and can be prescribed and monitored by a clinician.

Is it legal to import retatrutide for personal use?

FDA's personal importation policy describes narrow, discretionary circumstances for unapproved drugs, generally for serious conditions without domestic treatment options. An investigational obesity peptide with approved alternatives already on the market doesn't fit that narrow policy, and importing it carries real legal and safety risk.

How do I know if a retatrutide trial near me is actually recruiting?

Check the specific trial's ClinicalTrials.gov page for the recruitment status field (Recruiting, Active not recruiting, Completed, etc.) listed at the top of the record, then check the site-by-site status under Study Locations, since individual sites within one trial can have different statuses.

Does retatrutide work for type 2 diabetes too, more than obesity?

Yes, retatrutide has been studied in registered type 2 diabetes trials in addition to the obesity program, so the evidence base covers more than one indication, though none of those trials have resulted in FDA approval for either use.

Sources

1. Jastreboff AM et al., New England Journal of Medicine, 2023: 12 mg retatrutide produced 24.2% mean weight reduction at 48 weeks vs 2.1% for placebo; retatrutide is a GIP/GLP-1/glucagon triple agonist
2. ClinicalTrials.gov NCT04881760: Phase 2 obesity trial registration lists dose arms, comparators, route, and covers diabetes trials under the same program
3. ClinicalTrials.gov NCT05929066: Later-phase retatrutide trial registration listing enrollment criteria, comparators, and endpoints
4. ClinicalTrials.gov NCT05882045: Second later-phase retatrutide trial registration with independent dosing and design record
5. Drugs@FDA, FDA-approved drug products database: A Drugs@FDA query for retatrutide returns no approved product for any indication
6. Drugs@FDA, NDA 220934 (orforglipron/Foundayo): Orforglipron approved as Foundayo under NDA 220934 in six strengths; semaglutide and tirzepatide are approved as Ozempic/Wegovy and Mounjaro/Zepbound
7. 21 U.S.C. 353a(b)(1)(A)(i), Cornell Law: 503A compounding cascade requires a USP/NF monograph, or component of an approved drug, or presence on the Bulks List
8. 21 CFR 216.23, eCFR: The final 503A Bulks List contains exactly six substances, none of them peptides, and retatrutide is not among them
9. 21 CFR 216.24, eCFR: The separate 503B bulks list governing outsourcing facilities also does not include retatrutide
10. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA's public list of nominated bulk substances for 503A compounding does not include retatrutide
11. FDA, Bulk Drug Substances Nominated for Use in Compounding (PDF): FDA's nominations document records Category 1, 2, and 3 rosters as the authoritative source for interim compounding status
12. Federal Register, Docket FDA-2025-N-6895: FDA advisory committee met July 2026 to consider seven other peptides for the Bulks List; retatrutide was not included, and committee votes are non-binding absent rulemaking
13. 21 U.S.C. 355, Cornell Law: A new drug cannot be introduced into interstate commerce without an FDA-approved application
14. 21 CFR 201.128, eCFR: Intended use is established by labeling claims, advertising, and seller statements, not disclaimers
15. FDA, Personal Importation: FDA's personal importation policy describes narrow discretionary circumstances for unapproved drugs
16. NIDDK, Weight Management: NIDDK publishes neutral federal guidance on evidence-based weight management options